Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Pharmaceuticals and Signature Biosciences

Premium

Millennium Pharmaceuticals has received US Patent Number 6,342,351 “Methods and compositions for diagnosing and treating chromosome-18p related disorders.” The patent covers methods for diagnosis, genetic testing, and prognosis of bipolar affective disorder (manic depression). According to the invention, testing for the HKNG1 gene can be used as a diagnostic marker for bipolar affective disorder, as well as schizophrenia, attention deficit disorder, schizoaffective disorder, and unipolar affective disorders. A preferred method for detecting the HKNG1 gene involves a microarray containing nucleic acid probes for this gene.

 

Signature Biosciences of Hayward, Calif. was awarded US Patent Number 6,340,568, “Method for detecting and classifying nucleic acid hybridization.” The patent covers methods in which a detection system can sense the dielectric properties of hybridization complexes, and can use these properties as a measurement for distinguishing between different complexes. This system, an alternative to the use of fluorescent labels, can be used in expression analysis, sequencing, sequence verification, and other forms of nucleic acid analysis.

This patent award follows closely behind Signature’s receipt of US Patent Number 6,338,968, “Method and apparatus for detecting molecular binding events.” This previous patent also uses molecular structures with bielectric properties. It describes binding sites in which a test signal reacts with a probe.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more